Perioperative therapies for urological cancers

Junichi Inokuchi, Akira Yokomizo, Naotaka Nishiyama, Hiroshi Kitamura, Masatoshi Eto, Hiroyuki Nishiyama, Yoshihiko Tomita

研究成果: Contribution to journalReview article査読

1 被引用数 (Scopus)


Although surgery with curative intent is critical for management of many localized cancers, multimodal therapy including neoadjuvant and adjuvant therapy has been introduced to increase the effectiveness of local control of surgery and prolong survival. However, strong evidence supporting the utility of such multimodal therapy is limited. The utility of perioperative chemotherapy has been extensively investigated in bladder cancer, and several randomized controlled trials have indicated the benefit of neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer. Regrettably, perioperative therapy for other urological cancers is controversial; therefore, no definitive conclusions have been drawn. Recently, the number of trials has rapidly increased due to the development of immune checkpoint inhibitors, used alone or in combination with other modalities. In this review, we summarize the current status and supporting evidence for perioperative therapies such as neoadjuvant and adjuvant therapies for urological cancers, including prostate cancer, urothelial cancer and renal cell carcinoma.

ジャーナルJapanese journal of clinical oncology
出版ステータス出版済み - 4 1 2020

All Science Journal Classification (ASJC) codes

  • 腫瘍学
  • 放射線学、核医学およびイメージング
  • 癌研究


「Perioperative therapies for urological cancers」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。